Mannkind (MNKD) EBITDA (2010 - 2026)
Mannkind (MNKD) posted quarterly EBITDA of -$1.7 million for Q1 2026, down 107.48% year-over-year from $22.3 million in Q1 2025, and up 78.31% quarter-over-quarter from -$7.7 million in Q4 2025.
Mannkind (MNKD) EBITDA (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has reported EBITDA for 17 consecutive years, with -$1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 107.48% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at $14.8 million (down 81.01% YoY), while the FY2025 annual figure was $38.8 million, down 46.55% from the prior year.
- EBITDA climbed to -$1.7 million in Q1 2026 per MNKD's latest filing, from -$7.7 million in the prior quarter.
- Across five years, EBITDA topped out at $26.5 million in Q4 2024 and bottomed at -$21.3 million in Q1 2022.
- Historically, EBITDA has averaged $3.2 million across 5 years, with a median of $5.1 million in 2023.
- Annual changes were most pronounced in 2022 — EBITDA plunged 243.34% — and 2024, when it jumped 865.14%.
- Mannkind's EBITDA stood at -$12.8 million in 2022, then jumped by 161.44% to $7.9 million in 2023, then soared by 237.17% to $26.5 million in 2024, then tumbled by 129.01% to -$7.7 million in 2025, then jumped by 78.31% to -$1.7 million in 2026.
- Business Quant data shows MNKD's EBITDA at -$1.7 million in Q1 2026, -$7.7 million in Q4 2025, and $18.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | -350,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -350,000.00 |
| Mar 31, 2026 | -1.67 Mn |
| Dec 31, 2025 | -7.69 Mn |
| Sep 30, 2025 | 18.90 Mn |
| Jun 30, 2025 | 5.30 Mn |
| Mar 31, 2025 | 22.29 Mn |
| Dec 31, 2024 | 26.50 Mn |
| Sep 30, 2024 | 12.76 Mn |
| Jun 30, 2024 | 16.61 Mn |
| Mar 31, 2024 | 16.72 Mn |
| Dec 31, 2023 | 7.86 Mn |
| Sep 30, 2023 | 5.10 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Mar 31, 2023 | -6.00 Mn |
| Dec 31, 2022 | -12.79 Mn |
| Sep 30, 2022 | -9.61 Mn |
| Jun 30, 2022 | -20.45 Mn |
| Mar 31, 2022 | -21.26 Mn |
| Dec 31, 2021 | -23.97 Mn |
| Sep 30, 2021 | -6.59 Mn |